Yifan Pharmaceutical (002019) Fundamentals 2026 — P/E 35.1x, Revenue Analysis | SniperIQ
Yifan Pharmaceutical (002019) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥12.3B, trading at ¥10.13 on the SHZ. This SniperIQ fundamentals page covers Yifan Pharmaceutical's valuation (P/E 35.1x, P/B 1.4x), profitability (net margin 7.0%), revenue (¥5.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yifan Pharmaceutical's market cap?
Yifan Pharmaceutical (002019) has a market capitalization of approximately ¥12.3B, trading at ¥10.13 on the SHZ. Market cap moves with the live share price.
What is Yifan Pharmaceutical's P/E ratio?
Yifan Pharmaceutical's trailing twelve-month P/E ratio is 35.1x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yifan Pharmaceutical?
Yifan Pharmaceutical runs a net profit margin of 7.0%, a gross margin of 46.6%, and an operating margin of 8.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yifan Pharmaceutical generate?
Yifan Pharmaceutical reported revenue of ¥5.1B for fiscal year 2025, with net income of ¥402M and earnings per share (EPS) of 0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yifan Pharmaceutical pay a dividend?
Yifan Pharmaceutical offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yifan Pharmaceutical financially healthy?
Yifan Pharmaceutical carries a debt-to-equity ratio of 0.23x and a current ratio of 1.34x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yifan Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yifan Pharmaceutical (002019) the key facts are: market cap ¥12.3B, P/E 35.1x, revenue ¥5.1B, 52-week range 9.07-16.66. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yifan Pharmaceutical's full fundamentals live
Get Yifan Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.